Lead sponsor
AbbVie (prior sponsor, Abbott)
7 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
7
Trials led
0
Ongoing
2,347
Total enrollment
223
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
7
Trials by status
Completed
5
Terminated
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Diseasemild-to-moderate ADPh 2Completed438
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitorsmild-to-moderate ADPh 2Completed434
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Diseasemild-to-moderate ADPh 2Terminated349
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Diseasemild-to-moderate ADPh 2Terminated343
Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Completed274
Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Diseasemild-to-moderate ADPh 2Completed267
Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Diseasemild-to-moderate ADPh 2Completed242